Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butirprost is a nutraceutical combination product composed of sodium hyaluronate and an extract of *Plantago major* (greater plantain). It is primarily utilized as an adjuvant therapy in the management of chronic bacterial prostatitis (CBP). The product is designed to be used in conjunction with standard antibiotic treatments, such as fluoroquinolones, to enhance clinical outcomes. Sodium hyaluronate is known for its anti-inflammatory properties and its role in tissue repair and mucosal protection, while *Plantago major* provides additional anti-inflammatory and antimicrobial bioactive compounds. Clinical studies indicate that the administration of Butirprost significantly improves pain, urinary symptoms, and overall quality of life in patients with prostatic inflammation compared to antibiotic treatment alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Butirprost.